Global Inhaled Nitric Oxide (NO) Delivery Systems Market Size By Type (General Type, Intelligent Type), By Application (Infant, Adult), By Region, And Segment Forecasts, 2023 to 2032

The Global Inhaled Nitric Oxide (NO) Delivery Systems Market was valued at USD 810 million in 2023 and is projected to reach USD 1.43 billion by 2031, expanding at a CAGR of 7.3% during the forecast period from 2023 to 2031. Inhaled nitric oxide is a critical therapeutic agent widely used for treating respiratory failure, persistent pulmonary hypertension of the newborn (PPHN), and acute respiratory distress syndrome (ARDS). The demand for nitric oxide delivery systems is being bolstered by the increasing incidence of respiratory conditions, advancements in neonatal care, and the growing preference for non-invasive respiratory support technologies across intensive care settings.

Drivers:

Rising Prevalence of Respiratory Disorders:

An upsurge in the number of patients suffering from conditions such as PPHN, ARDS, and pulmonary hypertension is a key driver. Nitric oxide therapy offers selective pulmonary vasodilation, making it highly effective in managing these diseases.

Advancements in Neonatal and Pediatric Care:

Increasing investment in neonatal intensive care units (NICUs) and enhanced survival rates of preterm infants are contributing to the rising adoption of inhaled nitric oxide delivery systems.

Clinical Expansion of NO Applications:

New clinical studies exploring nitric oxide’s role in treating conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), and cardiac surgeries are widening the therapeutic landscape.

Restraints:

High Cost of Therapy and Equipment:

The cost associated with nitric oxide therapy—including gas supply and delivery system equipment—remains a challenge for healthcare systems in low- and middle-income countries, limiting market penetration.

Regulatory and Safety Concerns:

Strict regulatory frameworks and concerns related to safe handling and dosing of nitric oxide gas may hinder market adoption, especially in facilities lacking specialized staff or infrastructure.

Opportunity:

Development of Portable and Smart NO Delivery Devices:

There is a growing trend toward compact, intelligent, and user-friendly nitric oxide delivery systems. These devices enable point-of-care usage and home-based treatments, creating opportunities in both hospital and ambulatory settings.

Emerging Markets and Untapped Regions:

Countries in Asia-Pacific and Latin America are investing heavily in healthcare infrastructure. The unmet need for respiratory support in these regions offers a significant growth opportunity for market players.

Market by System Type Insights:

The market is segmented into Standalone NO Delivery Systems and Integrated NO Delivery Systems. In 2023, Standalone Systems dominated the market due to their flexibility and compatibility with a range of ventilators. However, Integrated Systems are expected to experience faster growth owing to their ease of use, compact design, and reduced need for technical expertise.

Market by End-use Insights:

Hospitals and Specialty Clinics held the largest market share in 2023, driven by the increasing number of admissions for neonatal and respiratory care. The Homecare Settings segment is expected to witness robust growth due to technological advancements enabling safe use of NO delivery systems in non-hospital environments.

Market by Regional Insights:

North America led the global market in 2023, supported by high awareness, favorable reimbursement policies, and widespread adoption of advanced respiratory therapies. Asia-Pacific is projected to register the fastest growth during the forecast period, spurred by improving healthcare infrastructure, growing healthcare expenditure, and rising prevalence of respiratory disorders.

Competitive Scenario:

Leading companies in the Global Inhaled Nitric Oxide Delivery Systems Market include Mallinckrodt Pharmaceuticals, Praxair, Inc. (Linde plc), Bellerophon Therapeutics, Vero Biotech LLC, and Novoteris. These players are focusing on product innovation, regulatory approvals, and strategic partnerships to enhance their market presence.

Key Developments:

In 2023, Vero Biotech launched a next-generation portable NO delivery system targeted at outpatient and home settings.

In 2024, Mallinckrodt Pharmaceuticals received expanded FDA approval for INOmax for use in pediatric cardiac surgery recovery.

Bellerophon Therapeutics is actively conducting trials for NO therapy in pulmonary fibrosis and COVID-19 treatment.

Scope of Work – Global Inhaled Nitric Oxide (NO) Delivery Systems Market

Report Metric Details

Market Size (2023) USD 810 million

Projected Market Size (2031) USD 1.43 billion

CAGR (2023–2031) 7.3%

Market Segments By System Type (Standalone, Integrated), End-use (Hospitals, Homecare), Region

Growth Drivers Increasing respiratory diseases, advanced neonatal care, clinical expansion

Opportunities Portable delivery systems, emerging market expansion

FAQs:

What is the current market size of the Global Inhaled Nitric Oxide (NO) Delivery Systems Market?

The market size was USD 810 million in 2023.

What is the major growth driver of the Global Inhaled Nitric Oxide (NO) Delivery Systems Market?

Increasing prevalence of respiratory conditions and rising use in neonatal intensive care.

Which is the largest region during the forecast period in the Global Inhaled Nitric Oxide (NO) Delivery Systems Market?

North America is the largest region, followed by Asia-Pacific as the fastest growing.

Which segment accounted for the largest market share in Global Inhaled Nitric Oxide (NO) Delivery Systems Market?

The Hospitals and Specialty Clinics segment held the largest share in 2023.

Who are the key market players in the Global Inhaled Nitric Oxide (NO) Delivery Systems Market?

Key players include Mallinckrodt Pharmaceuticals, Vero Biotech, Praxair (Linde plc), Bellerophon Therapeutics, and Novoteris.